HER2 Biomarkers
Guardant Health Receives Guardant360 CDx Regulatory Approval in Japan for HER2 Lung Cancer Treatment
Patients who test positive for a HER2 mutation and have seen their disease progress after chemotherapy can now be treated with Daiichi Sankyo's Enhertu.
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
Consortium Aims to Standardize IHC Biomarker Tests for Precision Medicine, Starting With HER2
Premium
The Consortium for Analytic Standardization hopes to bring an archaic technology into the 21st century by producing calibrated standards for the most utilized IHC-based biomarker tests.
Guardant Health, Thermo Fisher Scientific Tests Approved as CDx to Enhertu in Lung Cancer
The tests can now be used to identify patients with specific HER2-activating mutations that sensitize their tumors to the newly approved antibody-drug conjugate.
With recent response data galvanizing oncologists to expand access to anti-HER2 treatment, digital pathology firm Paige is ramping up efforts to create a companion test.